Sanofi's Phase III IRAKLIA trial evaluated Sarclisa for multiple myeloma, meeting co-primary endpoints when combined with pomalidomide and dexamethasone. The study showed promising results, aiming for regulatory filings and expanding treatment options.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing